Page last updated: 2024-10-22

albuterol and Inflammatory Response Syndrome, Systemic

albuterol has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, JH1
Lee, J1
Park, KS1
Hong, SW1
Gho, YS1

Other Studies

1 other study available for albuterol and Inflammatory Response Syndrome, Systemic

ArticleYear
Drug Repositioning to Alleviate Systemic Inflammatory Response Syndrome Caused by Gram-Negative Bacterial Outer Membrane Vesicles.
    Advanced healthcare materials, 2018, Volume: 7, Issue:13

    Topics: Albuterol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Repositioning; Ex

2018